One week from today, our Director of Life Sciences Harshita Ravishankar, MD MPA, will be presenting at the inaugural GLP-1-Based Therapeutics Summit in Philadelphia on real-world GLP-1 prescribing trends gleaned from Truveta Data

Muscle Injury Recovery and Regeneration Component peptide research in muscle injury models revealed complementary healing mechanisms[12]: BPC-157: Faster restoration of muscle architecture in crush injury models TB-500: Enhanced satellite cell activation and myofiber regeneration GHK-Cu: Improved collagen content and reduced fibrosis formation KPV: Modulation of inflammatory responses that can impair muscle regeneration Combined approach addresses injury repair, cellular recruitment, matrix quality, and inflammation control Bone and Cartilage Research Investigations in fracture models demonstrated effects on bone repair processes, including improved callus formation and mineralization, with GHK-Cus gene expression effects potentially enhancing osteoblast function[13]
newborn screening (acylcarnitine profile) in countries with universal screening
W.StanleyL.DavidH
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
For details on how GLP-1 medications work and clinical data, see Independent Wellnesss overview: What Is GLP-1